Unknown

Dataset Information

0

Reversal of the Apoptotic Resistance of Non-Small-Cell Lung Carcinoma towards TRAIL by Natural Product Toosendanin.


ABSTRACT: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively triggers cancer cell death via its association with death receptors on the cell membrane, but exerts negligible side effects on normal cells. However, some non-small-cell lung carcinoma (NSCLC) patients exhibited resistance to TRAIL treatment in clinical trials, and the mechanism varies. In this study, we described for the first time that toosendanin (TSN), a triterpenoid derivative used in Chinese medicine for pain management, could significantly sensitize human primary NSCLC cells or NSCLC cell lines to TRAIL-mediated apoptosis both in vitro and in vivo, while showing low toxicity against human primary cells or tissues. The underlying apoptotic mechanisms involved upregulation of death receptor 5 (DR5) and CCAAT/enhancer binding protein homologous protein, which is related to the endoplasmic reticulum stress response, and is further associated with reactive oxygen species generation and Ca2+ accumulation. Surprisingly, TSN also induced autophagy in NSCLC cells, which recruited membrane DR5, and subsequently antagonized the apoptosis-sensitizing effect of TSN. Taken together, TSN can be used to sensitize tumors and the combination of TRAIL and TSN may represent a useful strategy for NSCLC therapy; moreover, autophagy serves as an important drug resistance mechanism for TSN.

SUBMITTER: Li X 

PROVIDER: S-EPMC5314365 | biostudies-literature | 2017 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Reversal of the Apoptotic Resistance of Non-Small-Cell Lung Carcinoma towards TRAIL by Natural Product Toosendanin.

Li Xin X   You Ming M   Liu Yong-Jian YJ   Ma Lin L   Jin Pei-Pei PP   Zhou Ri R   Zhang Zhao-Xin ZX   Hua Baojin B   Ji Xiao-Jun XJ   Cheng Xiao-Ying XY   Yin Fangzhou F   Chen Yan Y   Yin Wu W  

Scientific reports 20170217


Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively triggers cancer cell death via its association with death receptors on the cell membrane, but exerts negligible side effects on normal cells. However, some non-small-cell lung carcinoma (NSCLC) patients exhibited resistance to TRAIL treatment in clinical trials, and the mechanism varies. In this study, we described for the first time that toosendanin (TSN), a triterpenoid derivative used in Chinese medicine for pain mana  ...[more]

Similar Datasets

| S-EPMC6760012 | biostudies-literature
| S-EPMC4373366 | biostudies-literature
| S-EPMC3905082 | biostudies-literature
| S-EPMC9755151 | biostudies-literature
| S-EPMC5528717 | biostudies-literature
| S-EPMC10549211 | biostudies-literature
| S-EPMC8538678 | biostudies-literature
| S-EPMC7549037 | biostudies-literature
| S-EPMC6770521 | biostudies-literature
| S-EPMC6013189 | biostudies-literature